<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8179">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01827904</url>
  </required_header>
  <id_info>
    <org_study_id>ET002</org_study_id>
    <nct_id>NCT01827904</nct_id>
  </id_info>
  <brief_title>ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors</brief_title>
  <official_title>A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective, randomized, double-blind (to subjects, local site's
      blinded assessor and  Tremor Core Lab assessors), crossover, multi-site, two-arm study
      (ExAblate treated arm Vs ExAblate Sham treated control arm) is to test the efficacy of
      treatment using the ExAblate Transcranial System and to further demonstrate safety in
      medication-refractory tremor in subjects with essential tremor (ET).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is evaluating a new technique for performing Thalamotomy for tremor control.
      While current techniques have possible invasive or radiation effects, the use of ExAblate if
      totally non-invasive and without any radiation. After informed consent and screening,
      eligible subjects will be randomized to either an ExAblate treatment or an ExAblate Sham or
      &quot;fake&quot; procedure.  The chance of randomization to Sham is one out of four. Subjects who are
      randomized to Sham Control will undergo the same procedure and follow-up visits through
      their Month 3 visit.  After the Month 3 assessments are complete, all subjects will be
      unblinded and those in the Sham treated group will have the option for an actual ExAblate
      treatment in an unblinded fashion, as long as they still qualify for ExAblate treatment. All
      subjects will be followed at 6 and 12 months and for up to 5 years as directed by their
      doctor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Severity of Device and Procedure related complications</measure>
    <time_frame>At the time of ExAblate Transcranial thalamotomy procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory Essential Tremor related to the ExAblate treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of of the ExAblate Transcranial MRgFUS treatment</measure>
    <time_frame>participants will be followed from the date of treatment until study completion, approximately up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effectiveness of the ExAblate Transcranial MRgFUS treatment of medication-refractory Essential Tremor (ET) will be determined using the Clinical Rating Scale for Tremor (CRST)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Transcranial ExAblate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcranial ExAblate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Transcranial ExAblate</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Treatment with Transcranial ExAblate</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial ExAblate</intervention_name>
    <arm_group_label>Transcranial ExAblate</arm_group_label>
    <other_name>ExAblate</other_name>
    <other_name>TcMRgFUS</other_name>
    <other_name>Thalamotomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Transcranial ExAblate</intervention_name>
    <arm_group_label>Sham Transcranial ExAblate</arm_group_label>
    <other_name>Sham Transcranial ExAblate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, age 22 years and older

          -  Subjects who are able and willing to give informed consent and able to attend all
             study visits

          -  Subjects with a diagnosis of Essential Tremor as confirmed from clinical history and
             examination by a neurologist or neurosurgeon specialized in movement disorder

          -  Subject exhibits a significant disability from their ET despite medical treatment

          -  Subjects should be on a stable dose of all ET medications for 30 days prior to study
             entry

          -  Subject is able to communicate sensations during the ExAblate Transcranial procedure

        Exclusion Criteria:

          -  Subjects with unstable cardiac status

          -  Severe hypertension

          -  Subjects with standard contraindications for MR imaging such as non-MRI compatible
             implanted metallic devices including cardiac pacemakers, size limitations, etc.

          -  Known intolerance or allergies to the MRI contrast agent including advanced kidney
             disease or severely impaired renal function

          -  Significant claustrophobia that cannot be managed with mild medication

          -  Current medical condition resulting in abnormal bleeding and/or coagulopathy

          -  Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within
             one week of focused ultrasound procedure or drugs known to increase risk or
             hemorrhage

          -  History of intracranial hemorrhage

          -  History of multiple strokes, or a stroke within past 6 months

          -  Subjects who are not able or willing to tolerate the required prolonged stationary
             supine position during treatment

          -  Are participating or have participated in another clinical trial in the last 30 days

          -  Subjects unable to communicate with the investigator and staff

          -  Subjects with a history of seizures within the past year

          -  Subjects with brain tumors
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Valenzuela</last_name>
      <phone>650-725-6930</phone>
      <email>tremorstudy@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Pejman Ghanouni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Reddick</last_name>
      <phone>410-328-4723</phone>
    </contact>
    <investigator>
      <last_name>Howard Eisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Fishman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna J Loomba</last_name>
      <phone>434-243-1435</phone>
      <email>FUSbrain@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>William Jeff Elias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Brown</last_name>
      <phone>206-320-3070</phone>
      <email>Focusedultrasound@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Ryder Gwinn, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maheleth Llinas</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>6121</phone_ext>
      <email>Maheleth.Llinas@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Schwartz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University (TWMU)</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takaomi Taira, Prof</last_name>
      <phone>+81 3-3353-8111</phone>
      <email>ttaira@nij.twmu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takaomi Taira, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Jung Kweon, RN</last_name>
      <phone>82-2-2227-4578</phone>
      <email>kweonej@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Jin Woo Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 11, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ExAblate Transcranial MRgFUS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
